Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. IMNM
IMNM logo

IMNM News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

IMNM News

Immunome Q1 Earnings Beat Expectations

May 12 2026seekingalpha

Immunome Submits NDA for Varegacestat Supported by Positive Phase 3 RINGSIDE Results

Apr 29 2026Newsfilter

Immunome CSO Sells Shares Under 10b5-1 Plan

Apr 05 2026Fool

Immunome Executive Share Sale Details

Apr 05 2026NASDAQ.COM

Immunome Grants Stock Options to New Employees

Mar 05 2026Yahoo Finance

Opaleye Management Sells Entire Stake in Immunome for $37.3 Million

Mar 04 2026Fool

Opaleye Management Exits Entire Stake in Immunome

Mar 04 2026NASDAQ.COM

Immunome Reports FY Loss and Declining Revenue Amid Public Offering

Mar 03 2026seekingalpha

IMNM Events

05/12 16:10
Immunome Submits NDA Application for Varegacestat
"This quarter reflects the progress we are making in building Immunome into a multi-program targeted oncology company," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome. "The NDA submission for varegacestat is an important milestone that reflects our commitment to improving the lives of patients with desmoid tumors, for whom new treatment options are still needed. We are also pleased that detailed Phase 3 RINGSIDE data were selected for oral presentation at ASCO. In parallel, we continue to advance our ADC pipeline, with IM-1021 progressing in Phase 1 and IM-1617 recently receiving IND clearance." Immunome expects its current cash position to fund operations into 2028.

IMNM Monitor News

Immunome Inc experiences significant drop amid fundraising announcement

Dec 17 2025

Immunome Inc Reports Positive Phase 3 Trial Results for Varegacestat

Dec 15 2025

IMNM Earnings Analysis

No Data

No Data

People Also Watch